Browse the evidence

Semaglutide treatment in Type 2 Diabetes Mellitus patients significantly reduces HbA1c, fasting plasma glucose, and body weight while improving renal markers (ACR) over a 12-month period.

If you have Type 2 Diabetes, Semaglutide is a highly effective treatment for lowering blood sugar (HbA1c) and losing weight. It is taken as a once-weekly injection, starting at a low dose to minimize side effects like nausea. This treatment also helps protect kidney function by reducing albumin in the urine. Consistency is key, as benefits are maintained over time.

Tirzepatide (2.5 mg weekly) significantly improves glycemic control and reduces body weight in patients with type 2 diabetes during Ramadan fasting, with a favorable safety profile characterized by mild gastrointestinal side effects and no reported hypoglycemia.

If you have type 2 diabetes and plan to fast during Ramadan, tirzepatide (2.5 mg weekly) can help improve your blood sugar and weight without causing low blood sugar. You might experience mild stomach issues like nausea, but these are usually manageable and do not require stopping the medication or breaking your fast. Consult your doctor to ensure it fits your overall treatment plan.

Discontinuation or interruption of GLP-1 agonist therapy (semaglutide) leads to rapid weight regain and loss of cardiometabolic benefits, with patients regaining approximately two-thirds of lost weight within one year.

If you stop taking semaglutide, you will likely regain about two-thirds of the weight you lost and lose the heart and blood sugar benefits within a year. The drug works only as long as you take it. If you face a supply shortage or side effects, do not just stop; contact your provider immediately to switch to an alternative or manage the transition, as stopping leads to rapid regain.

GLP-1 and GLP-1/GIP receptor agonists are associated with lower exposure-adjusted mortality rates compared to non-GLP-1 weight management agents.

Beyond weight loss, GLP-1 and GLP-1/GIP agonists may offer a mortality benefit compared to older weight loss drugs. This is a significant advantage for patients with obesity-related comorbidities.

GLP-1 receptor agonists (GLP-1RAs) significantly reduce alcohol consumption, cravings, and alcohol-related hospitalizations in patients with Alcohol Use Disorder (AUD), particularly in obese subgroups.

If you have AUD, especially if you are obese or have Type 2 Diabetes, GLP-1 medications (like Semaglutide or Exenatide) are showing promise in reducing drinking and cravings. They work by changing how your brain rewards alcohol. While they are injections and can cause stomach issues, these side effects often fade. They are not yet the standard first-line treatment for all AUD, but they are a strong option to discuss with your doctor, particularly if other treatments haven't worked.

Tirzepatide is a broadly acceptable and preferred long-term treatment for comorbid obesity and obstructive sleep apnea (COBOSA) by patients, offering efficacy comparable to CPAP with different adherence profiles.

If you have obesity and sleep apnea, tirzepatide is a valid, once-weekly treatment option that many patients prefer over CPAP. Discuss with your doctor if it's right for you, considering factors like cost, side effects, and your preference for injections vs. devices.

Reallocating 30 minutes of daily sedentary time to moderate-to-vigorous physical activity (MVPA) in young, healthy, active adults increases daily energy intake by approximately 113–120 kcal and alters appetite hormones (higher fasting ghrelin, lower postprandial PYY) to compensate for energy expenditure, without affecting hedonic food reward traits.

If you are already active and healthy, increasing your moderate-to-vigorous exercise by 30 minutes a day will likely make you hungrier and cause you to eat about 120 more calories. This is your body's natural way of balancing energy. To manage weight, you must consciously account for this increased intake rather than assuming exercise alone creates a deficit. If your goal is performance, use this hunger to fuel your activity.

GLP-1 receptor agonist use during radiation therapy causes rapid weight loss and anatomic changes that compromise immobilization reproducibility and dosimetric accuracy, necessitating adaptive radiotherapy or temporary holding of the medication.

If you are taking GLP-1 drugs (like Ozempic or Wegovy) while getting radiation, tell your radiation team immediately. These drugs cause weight loss and stomach changes that can make your radiation treatment less accurate. Your team may ask you to pause the drug or scan you more often to adjust the treatment plan. This is to keep you safe and ensure the radiation hits the tumor correctly.

Dose de-escalation (tapering) or low-dose maintenance therapy may modestly limit the rate and magnitude of weight regain compared to abrupt cessation, but robust randomized evidence is currently lacking.

If you want to stop your incretin medication, talk to your doctor about tapering the dose or extending the time between injections rather than stopping abruptly. While this might help slow down weight regain, it is not a guaranteed solution, and you should expect some regain. Continuing at a lower dose is generally better than stopping completely.

Nutrient-stimulated hormone (NuSH) therapies, including GLP-1 and dual/tri-agonists, produce significant weight loss and cardiometabolic improvements in real-world settings, though response heterogeneity, high discontinuation rates, and post-cessation weight regain remain unresolved challenges.

NuSH therapies (like semaglutide or tirzepatide) are highly effective for significant weight loss and metabolic health in real-world use, but they are not magic bullets. Expect a significant portion of people to not respond well, experience side effects leading to stopping the drug, or regain weight after stopping. Success requires individualized dosing, lifestyle support, and an understanding that obesity management is often a long-term commitment rather than a quick fix.

β-hydroxy-β-methylbutyrate (HMB, 3 g/day) has conditional utility for muscle hypertrophy, showing benefits primarily during high training stress or caloric deficits, but is largely neutral in well-fed, resistance-trained individuals.

If you are dieting or doing extremely high-volume training, 3g of HMB daily might help preserve muscle. If you are eating well and training normally, HMB is likely a waste of money as it shows no benefit in this group.

GLP-1 receptor agonists (GLP-1RAs), such as semaglutide, reduce 'food noise' (heightened, persistent food cue reactivity and food-related intrusive thoughts), which contributes to reduced energy intake and weight loss.

If you struggle with constant thoughts about food ('food noise') that make dieting hard, GLP-1 medications like semaglutide may help quiet those thoughts. This isn't just about feeling full; it's about reducing the mental obsession with food. Talk to your doctor about whether this medication is right for you, especially if you have a history of depression, as monitoring is important.

A pinitol-enriched beverage (PEB) derived from carob pods significantly reduces blood glucose levels in individuals with impaired glucose tolerance (IGT) compared to a sucrose-enriched beverage (SEB).

If you have impaired glucose tolerance, substituting your regular sugary drinks with a pinitol-enriched beverage (containing ~4g pinitol per 500ml) for 6 weeks may help lower your fasting blood glucose levels compared to drinking sucrose-sweetened beverages. This substitution works by modulating insulin secretion pathways rather than just reducing calorie intake.

Meal-triggered gastric contractility modulation (GCM) implantation in obese type 2 diabetes patients leads to significant weight loss and reduced systolic blood pressure compared to insulin therapy, while achieving comparable glycemic control with fewer medications.

For obese T2D patients struggling with weight gain from insulin, gastric electrical stimulation (GCM) offers a surgical alternative that promotes weight loss and lowers blood pressure while maintaining blood sugar control similar to insulin. It requires implantation and programming but may reduce medication burden.

Post-exercise intake of approximately 20g of protein reduces time below range (hypoglycemia) following moderate-intensity continuous training (MICT) in adults with Type 1 Diabetes.

If you have Type 1 Diabetes and do moderate continuous exercise (like jogging or cycling), eating about 20g of protein immediately after might help prevent low blood sugar overnight. This benefit was not seen with high-intensity interval training (HIIT). Always monitor your glucose and consult your care team before changing post-exercise nutrition.

Intermittent fasting (IF) promotes weight loss and metabolic health by inducing ketosis, improving insulin sensitivity, and regulating hunger hormones.

Try intermittent fasting, such as time-restricted eating (e.g., 16:8), to promote ketosis and regulate hunger hormones. It can be as effective as caloric restriction for weight loss.

In severely obese subjects, a carbohydrate-restricted diet improves insulin sensitivity independently of the amount of weight lost, compared to a low-fat diet.

For non-diabetic severely obese individuals, cutting carbs to 30g/day improves how your body handles insulin, even if you don't lose as much weight as someone on a low-fat diet. This suggests a direct metabolic benefit to carb restriction beyond just burning fewer calories.

A carbohydrate-restricted diet reduces triglyceride levels more effectively than a low-fat diet in severely obese subjects, particularly in those who lose more than 5% of their baseline weight.

If you are severely obese, a low-carb diet (≤30g/day) will lower your triglycerides much more than a low-fat diet, but this benefit is most pronounced if you actually lose more than 5% of your body weight. Simply restricting carbs without losing weight may not yield the same triglyceride benefits.

Alternate-day fasting improves cardiovascular risk markers by reducing total cholesterol, triglycerides, and LDL cholesterol, and increasing LDL particle size, though effects on HDL are inconsistent.

If you have high cholesterol or triglycerides, alternate-day fasting may help improve your numbers by lowering bad cholesterol and increasing the size of LDL particles, which is less atherogenic. Note that HDL improvements are not guaranteed.

A five-week low-glycemic index (LGI) diet significantly reduces total fat mass and improves postprandial lipid profiles in moderately overweight nondiabetic men, despite maintaining stable body weight.

Switch to low-glycemic carbohydrates (like whole grains, legumes, and non-starchy vegetables) for five weeks. Do not try to restrict calories; keep your food intake normal. You may not see a change on the scale, but you will likely lose abdominal fat and improve your blood lipid profile due to lower insulin spikes.

VLCDs improve cardiovascular risk factors, including lowering blood pressure, serum cholesterol, and improving glucose control in type II diabetics, though HDL cholesterol may decrease in women.

VLCDs can rapidly improve blood pressure, cholesterol, and blood sugar control in obese patients with these conditions. However, women should be aware that HDL ('good') cholesterol may drop, which is a known side effect of weight loss in women.

In non-diabetic patients, a ketogenic diet increases LDL cholesterol and total cholesterol compared to low-fat diets, whereas in diabetic patients, it improves lipid profiles by lowering triglycerides and raising HDL.

If you are non-diabetic and overweight, be aware that a ketogenic diet may raise your LDL and total cholesterol compared to a low-fat diet. If you have diabetes, a ketogenic diet tends to improve your triglycerides and HDL (good cholesterol). Monitor your lipids closely if you choose this diet.

Males with severe obesity experience significantly greater excess body weight loss and greater reduction in gamma-glutamyl transferase (a marker for NAFLD) compared to females following a 25-day very low-carbohydrate ketogenic diet (VLCKD).

If you are female, you may lose less weight and see less improvement in liver health markers than a male following the exact same very low-carb ketogenic diet protocol. This is likely due to differences in body fat distribution and hormones. Do not assume your results will match male benchmarks; focus on consistency and consult a professional to adjust expectations.

The sex-based difference in VLCKD efficacy is attenuated in post-menopausal females, who experience benefits more similar to males than pre-menopausal females.

If you are post-menopausal, your body's response to a very low-carb ketogenic diet may be more similar to a man's than to a pre-menopausal woman's. This is likely due to hormonal shifts. You may see better results than expected if you adjust your strategy to account for these changes rather than assuming you can't lose weight.